-
公开(公告)号：EP1944029B1
公开(公告)日：2011-12-21
申请号：EP06822589.5
申请日：2006-10-30
CPC分类号： A61K9/2813 , A61K9/2072 , A61K9/2081 , A61K9/2866 , A61K9/501 , A61K9/5021 , A61K9/5073 , A61K31/47
摘要： Disclosed is a pharmaceutical preparation having excellent photostability, which comprises a pitavastatin (which is an HMG-CoA reductase inhibitor) or a salt or ester thereof. The pharmaceutical preparation comprises a pitavastatin, titanium oxide and a coloring agent having a wavelength of maximum absorption falling within the range from 400 to 500 nm.
-
2.发明公开PHARMACEUTICAL PREPARATION HAVING EXCELLENT PHOTOSTABILITY 有权药剂师ZUBEREITUNG MIT HERVORRAGENDERPHOTOSTABILITÄT
公开(公告)号：EP1944029A1
公开(公告)日：2008-07-16
申请号：EP06822589.5
申请日：2006-10-30
CPC分类号： A61K9/2813 , A61K9/2072 , A61K9/2081 , A61K9/2866 , A61K9/501 , A61K9/5021 , A61K9/5073 , A61K31/47
摘要： The present invention relates to a pharmaceutical preparation of high photostability which contains pitavastatin, which is an HMG-CoA reductase inhibitor, a salt of pitavastatin, or an ester of pitavastatin. The pharmaceutical preparation contains a pitavastatin compound, titanium oxide, and a colorant having a maximum absorption wavelength of 400 nm to 500 nm.
摘要翻译： 本发明涉及高光稳定性的药物制剂，其含有匹伐他汀，其为HMG-CoA还原酶抑制剂，匹伐他汀的盐或匹伐他汀的酯。 药物制剂含有匹伐他汀化合物，二氧化钛和最大吸收波长为400nm〜500nm的着色剂。
-
3.发明公开CONTROLLED-RELEASE DRUG COMPOSITION 审中-公开ARZNEIMITTELZUSAMMENSETZUNG MIT KONTROLLERERTER FREISETZUNG
公开(公告)号：EP1514547A1
公开(公告)日：2005-03-16
申请号：EP03733434.9
申请日：2003-06-16
发明人： TANIZAWA, Yoshio , SHIMOKAWA, Tatsuharu , OGAWA, Hirotada , WATANABE, Mayumi , KOZAKI, Chihiro , KAWASHIMA, Hiroyuki , SHINODA, Yasuo , INAGI, Toshio
CPC分类号： A61K31/47 , A61K9/2081 , A61K9/209 , A61K9/5026 , A61K9/5036 , A61K9/5078 , A61K9/5084
摘要： The present invention is drawn to a pharmaceutical composition characterized by containing a composition (A) which contains pitavastatin, a salt thereof, or an ester thereof and which initiates release thereof at least in the stomach, and an enteric composition (B) which contains pitavastatin, a salt thereof, or an ester thereof. By use of the controlled release pharmaceutical compositlon of the present invention, the blood level of pitavastatin can be maintained at an appropriate level immediately after administration over a long period of time. Thus, highly safety and effective treatment of hypercholesterolemia can be performed.
摘要翻译： 本发明涉及一种药物组合物，其特征在于含有含有匹伐他汀，其盐或其酯并至少在胃中释放的组合物（A）和包含匹伐他汀的肠溶组合物（B） ，其盐或其酯。 通过使用本发明的控释药物组合物，可以在施用后立即将匹伐他汀的血液水平维持在适当的水平。 因此，可以进行高胆固醇血症的高度安全和有效的治疗。
-
公开(公告)号：EP0814782B1
公开(公告)日：2002-11-27
申请号：EP96942588.3
申请日：1996-12-20
发明人： MURAMATSU, Toyojiro , MASHITA, Katsumi , SHINODA, Yasuo , SASSA, Hironori , KAWASHIMA, Hiroyuki , TANIZAWA, Yoshio , TAKEUCHI, Hideatsu
CPC分类号： A61K9/2013 , A61K9/2009 , A61K31/47 , A61K47/02 , A61K47/183
摘要： Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4'-4'-fluorophenyl-2'-cyclopropyl-quinolin-3'-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has a pH of from 7 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.
-
公开(公告)号：EP0814782A1
公开(公告)日：1998-01-07
申请号：EP96942588.0
申请日：1996-12-20
发明人： MURAMATSU, Toyojiro , MASHITA, Katsumi , SHINODA, Yasuo , SASSA, Hironori , KAWASHIMA, Hiroyuki , TANIZAWA, Yoshio , TAKEUCHI, Hideatsu
CPC分类号： A61K9/2013 , A61K9/2009 , A61K31/47 , A61K47/02 , A61K47/183
摘要： Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4'-4'-fluorophenyl-2'-cyclopropyl-quinolin-3'-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has a pH of from 7 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
